Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 14, 795 (2008)
doi:10.1038/nm0808-795b
National Cancer Institute helps businesses cross 'the valley of death'
Prashant Nair1
- Boston
The San Diego–based biotechnology firm NovaRx develops new cancer therapeutics, including experimental approaches involving vaccines. Like many other small companies, NovaRx faces a funding hurdle in advancing drugs from its pipeline into human clinical trials, says executive vice-chairman Habib Fakhrai.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Human therapeutic proteins from silkwormsNature Biotechnology Research News (01 Jan 2003)
